Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) is a Healthcare company (Biotechnology) with a market capitalization of $828M. The Maz Rating grades it against the other companies in its sector.
Syndax Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $9.20, Syndax Pharmaceuticals, Inc. trades at 2.9x sales. Over the last twelve months it generated about $285M of revenue and a net loss of $210M. It runs a gross margin of 93.7%, an operating margin of -61.7% and a net margin of -72.4%. It shows return on equity of -804.4%, return on invested capital of -31.2% and a free cash flow yield of -21.4%. On the balance sheet: a debt-to-equity ratio of -34.31 and a current ratio of 4.69. Over the past 52 weeks the share price ranged from $9.03 to $25.59, with a beta of 0.37.
Syndax Pharmaceuticals, Inc. does not currently pay a dividend.
22 Wall Street analyst ratings cover the stock: 20 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Syndax Pharmaceuticals, Inc. (SNDX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 41.0% / 30% · (Cash+Inv) / Mkt Cap (36m) 38.4% / 30% · Interest income / Revenue 6.71% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 41.0% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 29.8% / 33% · Receivables / Mkt Cap (36m) 5.35% / 49% · Interest income / Revenue 6.71% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 41.0% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 29.8% / 33.33% · Receivables / Mkt Cap (24m) 5.35% / 33.33% · Interest income / Revenue 6.71% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 77.8% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 71.8% / 33.33% · Receivables / Avg Assets (4Q) 10.2% / 33.33% · Interest income / Revenue 6.71% / 5% | Fail |
| FTSE | Debt / Total Assets 84.9% / 33.33% · (Cash+ST Inv) / Total Assets 61.7% / 33.33% · (Cash+Recv) / Total Assets 72.7% / 33.33% · Interest income / Revenue 6.71% / 5% | Fail |
No. As of September 2026, Syndax Pharmaceuticals, Inc. (SNDX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Syndax Pharmaceuticals, Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m), (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 6.71% of each dividend: Syndax Pharmaceuticals, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.